

CURRICULUM VITAE

DATE PREPARED: November 4, 2009

PART I: General Information

Name: Michael Patrick Curry
Office Address: Beth Israel Deaconess Medical Center
110 Francis Street
Liver Center, Suite 7
Boston, MA 02215 United States
Phone: (617) 632-9852
Email: mcurry@bidmc.harvard.edu
Fax: (617) 632-1065
Place of Birth: Ireland

Education:

1992 M.B.,B.CH. (Medicine), Cum laude, National University of Ireland,
Galway
1995 MRCPI, The Royal College of Physicians of Ireland
2004 M.D. (Medicine), National University of Ireland, Galway

Postdoctoral Training:

07/92-06/93 Intern , Medicine, University College Hospital Galway
07/93-06/95 Resident , Medicine, University College Hospital Galway
07/95-12/98 Fellow , Gastroenterology, St. Vincents University Hospital, Dublin
06/98-12/99 Clinical Research Fellow (Health & Research Board of Ireland),
Gastroenterology, St. Vincent's University Hospital
02/00-12/02 Fellow , Gastroenterology and Hepatology, Beth Israel Deaconess
Medical Center, Boston

Licensure and Certification:

1992 Medical Council of Ireland
1995 Member of the Royal College of Physicians
1999 Certificate of General Professional Training, Royal College of
Physicians
2000 Massachusetts Registered Physician (Limited)
2001 Massachusetts Registered Physician (Temporary)
2002 Massachusetts Registered Physician (Full)
2003 Gastroenterology, Irish College of Higher Medical Training

Academic Appointments:

1998-1999 Lecturer in Medicine, Universtiy College Dublin, Dublin, Ireland.
2001-2006 Instructor in Medicine, Harvard Medical School, Boston, MA.
2006- Assistant Professor of Medicine, Harvard Medical School, Boston

Hospital or Affiliated Institution Appointments:

06/95-12/99 Registrar in Medicine, St. Vincent's University Hospital, Dublin, Ireland
02/00-05/02 Fellow in Medicine, Beth Israel Deaconess Medical Center, Boston, MA
05/02- Staff Physician in Medicine and Gastroenterology, Beth Israel
Deaconess Medical Center, Boston, MA
01/03- Medical Director of Liver Transplantation, Beth Israel Deaconess
Medical Center, Boston, MA

Hospital and Health Care Organization Clinical Service Responsibilities:

2002- Attending Physician in Medicine, Beth Israel Deaconess Medical Center
2002- Attending Physician in Gastroenterology and Hepatology, Beth Israel
Deaconess Medical Center
2002- Member, New England Consortium for Liver Transplantation

Major Administrative Responsibilities:

2003- Medical Director of Liver Transplantation, Beth Israel Deaconess
Medical Center

Major Committee Assignments:

Affiliated Inst

1996-1998 Nutritional Committee, St. Vincent's University Hospital, Dublin,
Ireland
2002- Liver Transplant Selection Committee, Beth Israel Deaconess Medical
Center
2003- Transplant Center Quality Improvement Committee, Beth Israel
Deaconess Medical Center
2008- Transplant Institute Morbidity and Mortality Committee [Chairperson],
Beth Israel Deaconess Medical Center

Regional

2009- UNOS Regional Review Board [Chairperson], Other
2009- New England Consortium for Liver Transplantation [Chairperson],
Other

National

2009- United Network for Organ Sharing Liver and Intestinal Committee,
UNOS

Professional Societies:

1995-	Royal College Physicians of Ireland, Member
1996-1999	Irish Society of Gastroenterology, Member
1998-	American Association for Study of Liver , Member
1998-1999	Irish Society of Immunology, Member
1998-1999	Irish Research Scientists Associations, Member
2000-	American Gastroenterology Association, Member
2001-	Massachusetts Medical Society, Member
2002-	European Association for Study of the Liver , Member
2006-	American Society of Transplantation, Member

Community Service Related to Professional Work:

1998-2000	Medical Advisor, Transfusion Positive
2003-2004	Member, American liver Foundation Patient and Family Committee
2004-	Member, Medical Advisory Committee, American Liver Foundation, New England Chapter

Editorial Boards:

2002-	Ad-Hoc Reviewer, New England Journal of Medicine
2003-	Ad-Hoc Reviewer, Transplantation
2007-	Ad-Hoc Reviewer, Hepatology
2007-	Ad-Hoc Reviewer, Alimentary Pharmacology and Therapeutics
2009-	Ad-Hoc Reviewer, Clinical Infectious Diseases
2009-	Ad-Hoc Reviewer, American Journal of Transplantation

Awards and Honors:

1992	Governing Board Gold Medal in Surgery, National University of Ireland, Galway
1992	Honors Degree, National University of Ireland, Galway
1993	Neill McDermott Award in Surgery, Irish Medical Organization
1997	Travel Bursary Award, American Association for the Study of Liver Disease
1998	Best Poster Award, Irish Society of Gastroenterology
1999	Presidents Choice (Poster Award), American Association for Study of Liver Disease
2000	Travel Bursary Award, American Association for the Study of Liver Disease
2007	Best Doctors in America 2007-2008, Best Doctors
2007	Boston's Best Doctors, , Boston Magazine 2007
2008	Patients' Choice Award, MDx Medical, Inc
2009	Clinical Infectious Disease Award for Outstanding Review, Clinical Infectious Diseases Editor

Part II: Research, Teaching, and Clinical Contributions

A. Narrative report of Research, Teaching, and Clinical Contributions

My research activities have included both basic science research and clinical research. I have a strong background in immunology and have completed a thesis on the innate immune responses in HCV infection. I continued my interest in HCV immunology during my fellowship at BIDMC by investigating the T cell responses in HCV/HIV co-infection. Since fellowship, I have focused on clinical research. I am the principal investigator in a number of clinical trials including investigation of new antiviral therapies for CMV following liver transplantation, the use of Rapamycin in liver transplant patients for treatment of renal dysfunction, and a trial of extracorporeal liver assist devices (ELAD) for acute on chronic liver failure. Additionally, I have a number of clinical research programs studying various aspects of end stage liver disease including the treatment of HCC with radiofrequency ablation, studying the effect of end stage liver disease on avascular necrosis of the hips and determining prognosis of ESLD by radiological imaging with CT scanning and Fibroscan. I am co-investigator on many trial evaluating novel antiviral agents in both HCV and HBV infection.

My teaching commitments include the following:

HMS GI Pathophysiology course from 2000 to present.

HMS abdominal exam course from 2000 to present.

Frequent attendance at the Department of Medicine M & M conferences, Firm conferences and resident lunch time lectures at BIDMC.

Annual lectures to Medical Residents at West Roxbury VA hospital and MetroWest medical center since 2002.

Supervision of GI and Hepatology fellows, Medical residents, Nurse Practitioners and Physician Assistants on GI and Hepatology service.

Coordinated the weekly Hepatology conferences for 2000-2002. My clinical activities are based in Hepatology and Transplant Hepatology and my main interests are liver transplantation, viral hepatitis, liver failure and portal hypertension. My clinical practice is based at BIDMC with 6 outpatient sessions, 1 procedure session and in-patient care. I supervise 6 dedicated transplant coordinators, hepatology fellows, rotating residents and nurse practitioners in the Hepatology Division. I chair the liver transplant selection committee and maintain evidenced-based protocols for the management of pre- and post-transplant patients. I am the Chairperson of the Quality Improvement Committee in the transplant center.

I am on Hepatology service for 12 weeks per year and participate in the Medical teaching attending service for 1 month each year.

B. Funding Information

- | | |
|-----------|---|
| 1999-2002 | P.I., Health Research Board of Ireland, Characterization of the innate B and T cell responses in chronic hepatitis C virus infection |
| 2000- | Investigator, Schering Plough Corporation, Long Term Peg Intron for Patients who have failed to respond to Rebetrone with Advanced Fibrosis |

- and Cirrhosis Secondary to Hepatitis C - the CoPilot Trial
- 2003-2005 Investigator, Idenix Pharmaceuticals, An Open-Label, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of NM283 When Administered Alone and in Combination with Pegylated Interferon alfa 2b (Peg-IFNa-2b) to Treatment Naïve Adults with Genotype-1 Chronic Hepatitis C. Protocol Number: NM08A-003
- 2003-2005 Investigator, N.I.H., VIRAHEP-C “ A Phase III, Multicenter, Open-Label Study to evaluate The Relative Efficacy of Pegylated Interferon and Ribavirin in African Americans versus Caucasian patients with Chronic Hepatitis C and Genotype 1”
- 2004- Investigator, Private Grant, Comparison of serum hyaluronic acid levels and FibroScan with histological evaluations of liver fibrosis in patients with persistently abnormal liver function tests.
- 2004-2005 Investigator, Schering Plough Corporation, Comparison of PEG-Intron 1.5 ug/kg/wk plus Rebetol vs PEG-Intron 1 ug/kg/wk plus Rebetol vs Pegasys 180 ug/wk plus Copegus in Previously Untreated Adult Subjects with Chronic Hepatitis C Infected with Genotype 1
- 2004-2005 Investigator, Cooley Pharmaceuticals, CPG 10101 Injection in Hepatitis C: A phase 1 blinded, placebo controlled, dose escalation study
- 2004-2005 Investigator, Vertex Pharmaceuticals, Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naïve Patients with Chronic Hepatitis C
- 2004-2005 Investigator, Schering Plough Corporation, Comparison of PEG Interferon alfa-2b plus Ribavirin given as fixed dose or on a weight optimized basis for treatment of chronic Hepatitis C in previously untreated adult subjects
- 2004-2005 P.I., Gilead, A Multi-center Phase II, Open-Label Study to Evaluate the Pharmacokinetics of Tacrolimus or Cyclosporine When Co-Administered with Adefovir Dipivoxil 10 mg to Patients Post-Liver Transplantation
- 2004-2005 Investigator, Idun Pharmaceuticals, A Dose Response Study of a Caspase Inhibitor in Hepatitis C Patients
- 2005- Investigator, Echosens, Comparison of FibroScan with Histological Evaluations of Liver Fibrosis in Patients with hepatitis B and C presenting for Liver Biopsy
- 2005 Investigator, Idenix Pharmaceuticals, A Randomized, Double Blind Trial of LdT (Telbivudine) versus Lamivudine in Adults with Compensated Chronic Hepatitis B: NV -02B-007
- 2005 Investigator, Otsuka Maryland Institute, Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients with Hyponatremia (SALT 2 Trial)
- 2005-2006 Investigator, Glaxo Smith Kline, A double-blind, randomized, placebo-controlled, multi-centre, dose ranging, parallel group, phase II study to assess efficacy, safety/ tolerability and pharmacokinetics of a thrombopoeitin receptor agonist, SB-497115-GR, when administered as

- 2005-2006 30, 50, and 75mg once daily for 12 weeks in subjects with Investigator, Idenix, An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies:
- 2005-2007 P.I., Roche Pharmaceuticals, A prospective, open-label, multi-center, randomized trial of the efficacy and safety of a long term calcineurin inhibitor free maintenance regimen with mycophenolate mofetil and sirolimus in recipients of an orthotopic liver transplant ML18423C
- 2007-2009- P.I., Glaxo Smith Kline, Chronic Liver Disease and Thrombocytopenia
P.I., Viropharma, 2007P000172, A Randomized, Double-blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants
- 2009- P.I., Schering Plough, 2007P000407, Interferon-Induced Graft Dysfunction After Liver Transplantation: A Multicenter Case-Control Study

C. Report of Other (Non-Funded) Activities

- P.I. Fibroscan Evaluation of Progression of Liver Fibrosis in Liver Transplant Patients.
- P.I. Progression of Hepatitis C in Renal Transplant Recipients candidates.
- P.I. The effect of liver volume on outcome of patients with end stage liver disease
- P.I. A Pilot Study to Evaluate the Efficacy and Safety of Targeting High Tacrolimus Trough Levels for First-line Treatment of Acute Rejection in HCV (+) Liver Transplant Recipients

D. Report of Teaching

1. Local contributions

a. Medical School Courses

2002	<u>Human Systems, Gastrointestinal</u>		<i>contact time</i>	<i>prep time</i>
	Special Session	8 Medical	2 hours/year	6 hours/year
	Faculty	Students	for 1 year(s)	for 1 year(s)
2002-	<u>ME600M.5 Core Medicine Clerkship I</u>		<i>contact time</i>	<i>prep time</i>
	Evaluator	1 Medical Students	4 hours/week for 56 week(s)	none reported
2004	<u>Human Systems, Gastrointestinal</u>			

	Minicase Faculty	8 Medical Students	<i>contact time</i> 2 hours/year for 1 year(s)	<i>prep time</i> 6 hours/year for 1 year(s)
2004	<u>Human Diseases, Gastrointestinal</u>			
2005	<u>Human Systems, Gastrointestinal</u>			
	Special Sessions Faculty	8 Medical Students	<i>contact time</i> 4 hours/year for 1 year(s)	<i>prep time</i> 6 hours/year for 1 year(s)
2006-	<u>Human Systems-Gastrointestinal</u>			
			<i>contact time</i>	<i>prep time</i>
2007-	<u>Human Systems-Gastrointestinal</u>			
c. Local Invited Presentations				

Grand Rounds

2000	Hepatology for the New Millennium., Roger Williams Medical Center, Providence, Rhode Island Lecturer: 30 participants, 1 hour contact time per year, 4 hours prep time per year			
2002-	Recent advances in the treatment of Hepatitis C Virus Infection., Hale Hospital, Haverhill, MA Lecturer: 20 participants, 1 hour contact time per year, 5 hours prep time per year			
2006	Liver Transplantation: an update on indications and outcome, Marlboro Hospital, Marlboro, MA Lecturer: 30 participants, 1 hour contact time per year, 4 hours prep time per year			
2007-	Liver Transplantation for HCV: what's real, what's not, Rhode Island Hospital, Providence, RI Lecturer: 30 participants, 1 hour contact time per year, 4 hours prep time per year			
2007	Management of Complication Associated with Liver Cirrhosis, Mary Lane Hospital, MA Lecturer: 30 participants, 1 hour contact time per year, 5 hours prep time per year			

- 2008 Management of Cirrhosis, St Vincent's Hospital, Worcester, MA
Lecturer: 40 participants, 1 hour contact time per year,
4 hours prep time per year
- 2008 Management of Portal Hypertension, Nashoba Valley Medical Centerl.
Ayer, MA
Lecturer: 20 participants, 1 hour contact time per year,
6 hours prep time per year
- 2008 Management of Cirrhosis: an Update, Jordan Hospital, Plymouth, MA
Lecturer: 30 participants, 1 hour contact time per year,
5 hours prep time per year
- 2008 Hepatocellular Carcinoma: Epidemiology to Cure, St Elizabeths
Medical Center, Boston, MA
Lecturer: 40 participants, 1 hour contact time per year,
5 hours prep time per year
- 2009- An update of HCV infection, St Luke's Hospital, New Bedford, MA
Lecturer: 20 participants, 1 hour contact time per year,
3 hours prep time per year
- 2009- Liver Transplantation: An Update, Lemuel Shattuck Hospital, Boston,
MA
Lecturer: 40 participants, 1 hour contact time per year,
2 hours prep time per year
- 2009- Hepatitis C: An Update, Jordan Hospital, Plymouth, MA
Lecturer: 0 participants, 1 hour contact time per year,
3 hours prep time per year

Seminar

- 2000 The Burden of Viral Hepatitis on Transplantation, Beth Israel
Deaconess Medical Center (West)
Lecturer: 30 participants, 1 hour contact time per year,
5 hours prep time per year
- 2004- Management of acute and chronic liver failure, V.A. Medical Center,
West Roxbury
Lecturer: 10 participants, 1 hour contact time per year,
5 hours prep time per year
- 2004 The Hepatic Innate Immune Response to HCV infection., Beth Israel
Deaconess Medical Center (West)
Lecturer: 20 participants, 1 hour contact time per year,

- 5 hours prep time per year
- 2004 The Hepatic Innate Immune Response to HCV infection., Beth Israel Deaconess Medical Center (West)
Lecturer: 20 participants, 1 hour contact time per year, 5 hours prep time per year
- 2005- Managment of acute liver failure, Framingham Union Hospital
Lecturer: 10 participants, 1 hour contact time per year, 5 hours prep time per year
- 2007 Viral Hepatitis and Pregnancy: risk to mother and baby, Boston IVF, Waltham,MA
Lecturer: 30 participants, 1 hour contact time per year, 6 hours prep time per year
- 2008 Liver Failure and Cardiac Surgery, Beth Israel Deaconess Medical Center
Lecturer: 30 participants, 1 hour contact time per year, 10 hours prep time per year
- 2008 HCC: an update on UNOS policy and transplantation, Beth Israel Deaconess Medical Center
Lecturer: 30 participants, 1 hour contact time per year, 4 hours prep time per year
- 2009- Epidemiology of HCV infection, New England AIDS Education and Training Center
Lecturer: 0 participants, 1 hour contact time per year, 4 hours prep time per year

d. Continuing Medical Education Courses

- 2000 Advances in management of Pancreatobiliary and Liver Disease,
Lecturer: 30 participants, 1 hour contact time per year, 5 hours prep time per year
- 2001 Update in Gastroenterology and Hepatology.
Lecturer: 50 participants, 1 hour contact time per year, 5 hours prep time per year
- 2004 Update in Internal Medicine
Lecturer: 200 participants, 1 hour contact time per year, 10 hours prep time per year
- 2005- Update in Internal Medicine

- 2006- Update in Internal Medicine
- 2007- Update In Internal Medicine
- 2008 An update in Hepatology and Liver Transplantation
Conference Leader: 6 participants, 24 hours contact time per year,
30 hours prep time per year
- 2008 An Update in Hepatology and Liver Transplantation
Conference Leader: 6 participants, 24 hours contact time per year,
30 hours prep time per year
- 2008- Advances in Gastroenterology
- 2008 Primed East
Lecturer: 600 participants, 1 hour contact time per year, no prep time
reported

e. Advisory and Supervisory Responsibilities in Clinical or Laboratory Setting

- 2008 1 Fellows for 80 hrs/year, Supervising in ambulatory Clinic and
Hospital Rounds, Albany Medical Col. Of Union U.
- 2008-2009 1 Fellows for 500 hrs/year, Supervising in ambulatory clinic and
Hospital rounds, Beth Israel Deaconess Medical Center

2. Regional, national, or international contributions

a. Invited Presentations

National

- 2004- Cirrhosis & Steatosis-Overview, Evaluation, Medical Management and
the Non-operative Interventions, American Hepatobiliary
Association[*Invited Lecture*]
- 2004- Hepatorenal syndrome, 2004 Horizons Conference, North American
Critical Care Nurses Conferences[*Invited Lecture*]

International

- 1997 Hepatitis C: Current Challenges and Future Directions., Academy of
Medical Laboratories Science of Ireland[*Invited Lecture*]

- 1997 Viral Hepatitis; the risk to the health care professional., Phlebotomy Association of Ireland Annual Meeting, Dublin, Ireland.*[Invited Lecture]*
- 1997 Hepatitis C Infected Anti-D Immunoglobulin: A Unique Cohort of Patients., Update in Gastroenterology and Hepatology, Boston University Medical Center in collaboration with St*[Invited Lecture]*
- 1999 Advances in the Treatment of Chronic Hepatitis C., Transfusion Positive Annual Meeting, Dublin, Ireland. *[Invited Lecture]*
- 2003- Future Management and treatment of HCV infection., Trinity College Dublin, Ireland*[Invited Lecture]*

E. Report of Clinical Activities

- 2002- Medicine, Hepatology, Beth Israel Deaconess Medical Center (West)
Clinical Activity Description: My clinical activity includes both general gastroenterology, hepatology and transplant hepatology and involves the outpatient and inpatient care of patients with complex GI and liver conditions. My areas of particular interest include management of patients with end-stage liver disease, portal hypertension, viral hepatitis and those that require liver transplantation
Patient Load: 100 patients per week; Patients are highly complex especially those with end-stage liver disease requiring liver transplant
Clinical Contributions: I am the director of quality care for the liver transplant program at Beth Israel Deaconess Medical Center. I have prepared the policy and procedure manual for care of liver transplant recipients.

Part III: Bibliography

Original Articles

1. Crosbie OM, Freaney R, McKenna MJ, Curry MP, Hegarty JE. Predicting bone loss following orthotopic liver transplantation. *Gut*. 1999;44(3):430-4.
2. Curry MP, Golden-Mason L, Nolan N, Parfrey NA, Hegarty JE, O'Farrelly C. Expansion of peripheral blood CD5+ B cells is associated with mild disease in chronic hepatitis C virus infection. *J Hepatol*. 2000;32(1):121-5.
3. Golden-Mason L, Curry MP, Nolan N, Traynor O, McEntee G, Kelly J, Hegarty JE, O'Farrelly C. Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver. *Hepatology*. 2000;31(6):1251-6.
4. McKiernan SM, Hagan R, Curry M, McDonald GS, Nolan N, Crowley J, Hegarty J, Lawlor E, Kelleher D. The MHC is a major determinant of viral status, but not

fibrotic stage, in individuals infected with hepatitis C. *Gastroenterology*. 2000;118(6):1124-30.

5. MacEneaney PM, Malone DE, Skehan SJ, Curry MP, Miller JC, Gibney RG, Traynor O, McCormick PA. The role of hepatic arterial Doppler ultrasound after liver transplantation: an 'audit cycle' evaluation. *Clin Radiol*. 2000;55(7):517-24.
6. Curry MP, Norris S, Golden-Mason L, Doherty DG, Deignan T, Collins C, Traynor O, McEntee GP, Hegarty JE, O'Farrelly C. Isolation of lymphocytes from normal adult human liver suitable for phenotypic and functional characterization. *J Immunol Methods*. 2000;242(1-2):21-31.
7. Maguire OC, Curry MP, O'Gorman P, Parfrey N, Hegarty J, Cunningham SK. In vitro cold activation of complement shown by an overestimation of total complement 4: a study in patients with hepatitis C virus infection. *Ann Clin Biochem*. 2001;38(Pt 6):687-93.
8. MacDonald AJ, Duffy M, Brady MT, McKiernan S, Hall W, Hegarty J, Curry M, Mills KH. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. *J Infect Dis*. 2002;185(6):720-7.
9. Curry MP, Deignan T, Doherty DG, Golden-Mason L, Volkov Y, Norris S, Nolan N, Traynor O, McEntee G, Hegarty JE, O'Farrelly C. Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection. *J Hepatol*. 2002;37(1):101-8.
10. Duffy M, Salemi M, Sheehy N, Vandamme AM, Hegarty J, Curry M, Nolan N, Kelleher D, McKiernan S, Hall WW. Comparative rates of nucleotide sequence variation in the hypervariable region of E1/E2 and the NS5b region of hepatitis C virus in patients with a spectrum of liver disease resulting from a common source of infection. *Virology*. 2002;301(2):354-64.
11. Norris S, Doherty DG, Curry M, McEntee G, Traynor O, Hegarty JE, O'Farrelly C. Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy. *Cancer Immunol Immunother*. 2003;52(1):53-8.
12. Curry MP, Golden-Mason L, Doherty DG, Deignan T, Norris S, Duffy M, Nolan N, Hall W, Hegarty JE, O'Farrelly C. Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus infected liver. *J Hepatol*. 2003;38(5):642-50.
13. Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, Horsburgh R, Craven D, Sherman KE, Koziel MJ. Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. *Hepatology*. 2004;40(1):125-32.
14. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, Walsh A, Hegarty J, Lawlor E, Kelleher D. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. *Hepatology*. 2004;40(1):108-14.
15. Johnson SR, Pavlakis M, Khwaja K, Karp SJ, Curry M, Curran CC, Monaco AP, Hanto DW. Intensive Care Unit Extubation Does Not Preclude Extrarenal Organ Recovery from Donors after Cardiac Death. *Transplantation*. 2005;80(9):1244-1250.

16. Johnson SR, Alexopoulos S, Curry M, Hanto DW. Primary Nonfunction (PNF) in the MELD Era: An SRTR Database Analysis. *Am J Transplant.* 2007.
17. Cárdenas A, Curry M, Afdhal NH. The Not So Good Effects of Nitric Oxide Inhibition with Methylene Blue in Cirrhosis and Ascites. *Dig Dis Sci.* 2007.
18. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. *J Hepatol.* 2007.
19. Ho KJ, Owens CD, Johnson SR, Khwaja K, Curry MP, Pavlakis M, Mandelbrot D, Pomposelli JJ, Shah SA, Saidi RF, Ko DS, Malek S, Belcher J, Hull D, Tullius SG, Freeman RB, Pomfret EA, Whiting JF, Hanto DW, Karp SJ. Donor postextubation hypotension and age correlate with outcome after donation after cardiac death transplantation. *Transplantation.* 2008;85(11):1588-94.
20. Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. *J Gastroenterol Hepatol.* 2009;24(4):564-8.
21. Rogers CC, Johnson SR, Mandelbrot DA, Pavlakis M, Horwedel T, Karp SJ, Egbuna O, Rodrigue JR, Chudzinski RE, Goldfarb-Rumyantzev AS, Hanto DW, Curry MP. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients. *Clin Transplant.* 2009.
22. Subramanian A, Sulkowski M, Barin B, Stablein D, Curry M, Nissen N, Dove L, Roland M, Florman S, Blumberg E, Stosor V, Jayaweera DT, Huprikar S, Fung J, Pruett T, Stock P, Ragni M. MELD is an Important Predictor of Pre-Transplant Mortality in HIV-Infected Liver Transplant Candidates. *Gastroenterology.* 2009.

Reviews/Chapters/Editorials

1. Curry MP, Hegarty JE. Gallbladder and Biliary Tree in Cystic Fibrosis. In: *Diseases of the gall bladder and biliary tract.* Afdhal. New York: Marcel Dekker;2000. p. 387-406.
2. Curry MP, Koziel M. The dynamics of the immune response in acute hepatitis B: new lessons using new techniques. *Hepatology.* 2000;32(5):1177-9.
3. Curry MP, Koziel M. Immunobiology of Hepatitis Viruses. In: *Hepatitis Viruses.* Ou JHJ. Academic Press;2001. p. 171-212.
4. Curry MP Chopra S. Acute Viral Hepatitis. In: *Mandell, Douglas and Bennett's principles and practice of Infectious Disease.* Mandell, Bennett, Dolin editors. Elsevier;2004.
5. Curry MP. New Developments in the treatment of Hepatitis C. *Forum: Journal of the Irish College of General Practitioners.* 2004;21(1):35-36.
6. Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. *Transplantation.* 2004;78(7):955-63.
7. Curry MP Chopra S. Hepatic Vascular Disorders. *Hepatology: a practical approach.* Al Knawy B, Shiffman M, Weisner R editors. 2005.
8. Curry MP, Hegarty JE. The gallbladder and biliary tract in cystic fibrosis. *Curr*

- Gastroenterol Rep. 2005;7(2):147-53.
9. Curry MP, Afdhal NH. Use of growth factors with antiviral therapy for chronic hepatitis C. *Clin Liver Dis.* 2005;9(3):439-51.
 10. Karp SJ, Ku Y, Johnson S, Khwaja K, Curry M, Hanto, D. Surgical and Non-surgical Treatment for Hepatocellular Cancer. *Current Opinion in Transplantation.* 2006;11(3):226-233.
 11. Curry MP, Afdhal NH. Prophylaxis Against Recurrent HBV Infection after Liver Transplantation. In: *Current Hepatitis Reports.* Current Science Inc;2007.
 12. Afdhal NH, Curry M. Technology evaluation: A critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. In: *J Hepatol.* Elsevier;2007. p. 543-545.

Clinical Communications

1. Neelamekam TK, Geoghegan JG, Curry M, Hegarty JE, Traynor O, McEntee GP. Delayed correction of portal hypertension after portal vein conduit arterialization in liver transplantation. *Transplantation.* 1997;63(7):1029-30.
2. McCormick PA, Kennedy F, Curry M, Traynor O. COX 2 inhibitor and fulminant hepatic failure. *Lancet.* 1999;353(9146):40-41.
3. Lima M, Hanto D, Curry M, Wong M, Dang X, Koranik I. Atypical radiological presentation of progressive multifocal leukoencephalopathy following liver transplantation. *J Neurovirol.* 2005;11(1):46-50.

Thesis

1. Curry, MP. Characterization of the innate B and T cell responses in chronic hepatitis C virus infection. Galway, Ireland: National University of Ireland;2004.

NonPrint Materials

1. Curry MP Afdhal NH. Non-invasive markers of hepatic fibrosis. Rose BD (Editor). Wellesley (MA): Up TO date [CD ROM];2000.
2. Curry MP Afdhal, NH. Hepatic Adenoma. Rose BD (Editor). Wellesley (MA): Up To Date[CD Rom] ;2002.
3. Curry MP Chopra S. Hepatic Hemangioma. Rose BD (Editor). Wellesley (MA): Up to Date [CD Rom];2002.
4. Wissam Bleibel Michael Curry Sanjiv Chopra. Nodular Regenerative Hyperplasia. Boston, MA: Uptodate;2008.

Abstracts

1. Curry MP, Blake M, McCormick A, Hegarty JE, Malone D, Gibney R, O'Donoghue D. Combined Radiological and Endoscopic Management of Biliary obstruction – A

- 5-year follow-up. *Irish Journal of Medical Science*. 1996.
2. Curry MP, Kaminski G, Dooley S, Traynor O, McEntee G, McCormick A, Nolan N, Parfrey NA, Hegarty JE. Hepatitis G Virus infection following Liver Transplantation. *Irish Journal of Medical Science*. 1996.
 3. Crosbie OM, Curry M, Freaney R, McKenna M, Hegarty JE. Bone loss in chronic liver disease and following liver transplantation. *Hepatology*. 1997;26(4):347A.
 4. McKiernan S, Hagan R, Curry M, Hegarty J, Lawlor E, Kelleher D. Human Leukocyte Antigens related to disease outcomes in hepatitis C. *Hepatology*. 1998;28(4):214A.
 5. Curry MP, Smith F, Norris S, Doherty D, Golden-Mason L, McEntee G, Traynor O, Nolan N, Hegarty JE, O'Farrelly C. Intrahepatic gamma delta T lymphocytes are proportionately reduced in advanced Primary biliary cirrhosis. *Hepatology*. 1998;28(4):545A.
 6. Duffy M, Curry M, McKiernan S, Hegarty J, Kelleher D, Hall WW. Longterm genetic variation of hepatitis C virus in a cohort of patients infected from a single source. *Hepatology*. 1998;28(4):683A.
 7. Curry MP, Golden-Mason L, Hannigan E, Parfrey N, Hegarty JE, O'Farrelly C. Peripheral Blood CD5pos, IgM B lymphocytes are increased in chronic hepatitis C virus infection. *Hepatology*. 1998;28(4):360A.
 8. Golden-Mason L, Curry MP, Traynor O, McEntee GP, Kelly J, Hegarty JE, O'Farrelly C. Differentiating Haematopoietic stem cells in the adult human liver suggest a lymphoid bias. *Hepatology*. 1998;28(4):521A.
 9. Golden-Mason L, Curry MP, Traynor O, McEntee G, Kelly J, Hegarty JE, O'Farrelly C. Hepatic haemopoietic stem cells in end-stage alcoholic liver disease. *Hepatology*. 1998.
 10. Golden-Mason L, Curry MP, Nolan N, Traynor O, McEntee G, Kelly J, Hegarty JE, O'Farrelly C. Differentiating hematopoietic stem cells in tumor bearing adult human liver. *Hepatology*. 1999;30(4):253A.
 11. Curry MP, McKiernan S, Reilly M, Nolan N, McDonald GSA, Kelleher D, Hegarty JE. Follow-up of chronic hepatitis C virus genotype 1b infection in a unique cohort. *Hepatology*. 1999;30(4(2)):267A.
 12. Golden-Mason L, Curry MP, Traynor O, McEntee G, Kelly J, Hegarty JE, O'Farrelly C. Hepatic hemopoietic stem cells in end-stage alcoholic liver disease. *Hepatology*. 1999;30(4):255A.
 13. Curry MP, Doherty DG, Norris S, Deignan T, Golden-Mason L, Hegarty JE, O'Farrelly C. Increased expression of CD81, the hepatitis C receptor on CD5 pos B cells. *Hepatology*. 1999;30(4):456A.
 14. Curry MP, Doherty DG, Deignan T, Norris S, Morsy MA, McEntee G, Traynor O, Hegarty JE, O'Farrelly C. Intrahepatic TH1 cells but not natural T cells are expanded in chronic hepatitis C virus infection. *Hepatology*. 1999;30(4):351A.
 15. McKiernan S, Hagan R, Curry MP, Hegarty JE, Lawlor E, Kelleher D. Major histocompatibility complex class I antigens in hepatitis C infection. *Hepatology*. 1999;30(4):593A.

16. McKiernan S, Daly J, Curry MP, Hegarty JE, Kelleher D. Polymorphisms of TNF-alpha gene promoter region in hepatitis C infection. *Hepatology*. 1999;30(4):360A.
17. McKiernan S, Hagan R, Daly J, Curry MP, Hegarty JE, Lawlor E, Kelleher D. Tumour necrosis factor-alpha microsatellite polymorphisms extend the MHC haplotype in hepatitis C infection. *Hepatology*. 1999;30(4(2)):357A.
18. MacDonald AJ, Duffy M, Curry MP, Hegarty JE, McKiernan S, Mills KHG. A peptide of hepatitis C virus core protein generates T cells with a regulatory phenotype: implications for persistence of the infection. *Hepatology*. 2000;32(4):273A.
19. Deignan T, Curry MP, Doherty DG, Kelly A, McEntee G, Traynor O, Hegarty JE, O'Farrelly C. Hepatic natural T cells expressing the V alpha 24 T cell receptor are increased in hepatitis C virus infection and show skewed interferon-alpha production. *Hepatology*. 2000;32(4):294A.
20. Golden Mason L, Kelly A, Curry MP, Kelly J, Traynor O, McEntee G, Hegarty JE, O'Farrelly C. Interleukin-7 mRNA and protein levels in the normal adult liver: implications for hepatic T-cell differentiation. *Hepatology*. 2000;32(4):202A.
21. Graham C, Curry MP, He Q, Afdhal NH, Cheney C, Nunes D, Fleming C, Craven D, Koziel M J. Cytokine responses to hepatitis C virus (HCV) in intrahepatic CD4+enriched lymphocytes in HCV versus HIV/HCV co-infected patients. *Hepatology*. 2001;34(4):481A.
22. Golden-Mason L, Doherty DG, Curry MP, Norris S, Deignan T, Traynor O, McEntee GP, Hegarty JE, O'Farrelly C. Natural killer cell receptor expression: changes in hepatic natural killer (NK) and natural T cell (NT) populations in HCV infection. *Hepatology*. 2001;34(4):437A.
23. Golden-Mason L, Douek DC, Curry MP, Kelly J, McEntee G, Traynor O, Hegarty JE, O'Farrelly C. The adult human liver is not a site for conventional alpha-beta TCR+ T cell development. *Hepatology*. 2001;34(4):492A.
24. Oh S, Curry MP, Muslu H, Bhaskar KR, Perides G, Afdhal NH. Non-invasive markers of hepatic fibrosis in nonalcoholic fatty liver disease. *Gastroenterology*. 2002;122(4):670A.
25. O'Brien C, O'Brien M, Golden-Mason L, Curry MP, Donaldson P, Hegarty JE, O'Farrelly C. A polymorphism in the interferon gamma gene is not predictive of spontaneous viral clearance or disease progression in HCV infections in a homogenous population of Irish Women. *Hepatology*. 2002;36(4):541A.
26. Oh S, Benson A, Grossman J, Nasser I, Curry MP, Afdhal NH. Non-invasive markers of fibrotic nonalcoholic steatohepatitis. *Gastroenterology*. 2003;124(4):743A.
27. Lawitz E, Cantu N, Davis M, Afdhal N, Curry MP, et al. Triple therapy compared standard pegylated interferon alfa 2B + weight based ribavirin for treatment naive chronic hepatitis C (Tristar Trial): final results. *Hepatology*. 2003;(4(2)):636A.
28. Lawitz E, Cantu N, Davis M, Afdhal N, Curry MP et al. Triple therapy compared to standard pegylated interferon alfa 2B + weight based ribavirin for previous non-responders and relapsers with chronic hepatitis C. *Hepatology*. 2003;(4(2)):742A.

29. Lawitz E, Harrison S, Cantu N, Kadakia SC, Ganeshappa KP, Adam F, Davis M, Sperling R, Tsai N, Gasic A, Kothari T, Cox J, Sanders B, Silverman B, Ghandour E, Medoff J, Prasad V, Afdhal N, Maillard M, Curry MP. The effect of amantadine on sustained virologic response when added to pegylated interferon alfa 2B + weight based ribavirin in previous non-responders and relapsers. *Gastroenterology*. 2004;126(4):697A.
30. Lawitz E, Cantu N, Harrison S, Kadakia S, Adams F, Davis M, Sperling R, Tsai N, Gasic A, Kothari T, Ganeshappa KP, Cox J, Sanders B, Silverman B, Ghandour E, Medoff J, Afdhal N, Maillard M, Curry MP. The outcome of hepatitis C therapy in African Americans and Hispanics with persistently normal transaminases. *Gastroenterology*. 2004;126(4):696A.
31. Curry MP, Robson SC, Savitz S, Williams C, Gitlin N. Elevated ALT & AST due to Pegylated Interferon-a induced polymyositis in treated patients with undetectable hepatitis C viral load. *Hepatology*. 2004;40(4):344A.
32. Curry MP, Cardenas A, Afdhal NH. Effect of maintenance peg-intron therapy on portal hypertension and its complications: results from the copilot study. *Journal of Hepatology*. 2005;42(2):40.
33. Wong M, D'Agata E, Curry MP, Johnson S, Nagy S, Khwaja K, Karp S, Hanto D. Evolution of antimicrobial resistance in bacteria and yeast in a newly established liver transplant program. *American Journal of Transplantation*. 2005;5:508.
34. Wissam Bleibel, Scott R Johnson, Taranga Ghosh, Bishal Mainali, Khalid Khwaja, Seth Karp, Douglas W Hanto, Michael P Curry. Computed Tomography liver volumetrics predicts outcome in patients with endstage liver disease. *Am J Transplant*. 2006;1(1):543.
35. Christin Rogers, Scott Johnson, Emily Snow, Douglas Hanto, Khalid Khwaja, Seth Karp, Ogo Egbuna, Didier Mandelbrot, Martha Pavlakis, Michael Curry. Early Sirolimus conversion is superior to late Sirolimus conversion in reversing renal dysfunction in liver transplant recipients. *Am J Transplant*. 2006;1(1):232.
36. Ogo Egbuna, Scott Johnson, Martha Pavlakis, Khalid Khwaja, Seth Karp, Christin Rogers, Michael Curry, Emily Snow, Douglas Hanto, Didier Mandelbrot. Efficacy and safety of conversion from calcineurin inhibitors to Sirolimus after early steroid withdrawal kidney transplantation. *Am J Transplant*. 2006;1(1):515.
37. Scott R Johnson, Michael Curry, Sophocles Alexopoulos, Seth Karp, Khalid Khwaja, Douglas W Hanto. Local variation in the occurrence of primary graft non-function in liver transplantation. *Am J Transplant*. 2006;1(1):543.
38. Paula Ferrada, Darren Brennan, Michael P Curry, Imad Nasser, Scott R Johnson, Khalid Khwaja, Seth Karp, Shraga N Goldberg, Douglas W Hanto. Radiofrequency ablation of hepatocellular carcinoma is safe and effective in controlling tumor growth in wait listed liver transplant candidates. *Am J Transplant*. 2006;1(1):973.
39. Rogers C, Johnson S, Gribbons M, Khwaja K, Karp S, Egbuna O, Mandelbrot D, Pavlakis M, Hanto D, Curry M. Timing of Sirolimus conversion influences recovery of renal function in liver transplant recipients. *American Journal of Transplantation*. 2007;7(2):312.
40. R Malik, M Lai, K Bhaskar, I Nasser, M Curry, D Schuppan, N Afdhal.

- Identification of biomarkers that measure disease activity in patients with non alcoholic fatty liver disease. *Journal of Hepatology*. 2008;48(Suppl 2):S355.
41. James R Rodrigue, Timothy Antonellis, David R Nelson, Alan I Reed, Douglas W Hanto, Michael Curry. A cross sectional study of fatigue before and after liver transplantation. *American Journal of Transplantation*. 2008;8(Suppl 2):334.
 42. Jean Francis, Matthew Palmer, Michael Curry, Parul Patel, Martha Pavlakis, Scott Johnson, Seth Karp, Khalid Khwaja, Kevin Donohoe, Doug Hanto, Didier Mandelbrot. Evaluation of native Kidney (NK) recovery after simultaneous liver-kidney transplantation(SLK). *American Journal of Transplantation*. 2008;8(Suppl 2):337.
 43. James R Rodrigue, Gail L Lisson, David R Nelson, Alan I Reed, Michael Curry, Douglas W Hanto. MELD and prediction of Quality of Life one year after liver transplantation. *American Journal of Transplantation*. 2008;8(Suppl 2):220.
 44. James R Rodrigue, Timothy Antonellis, Douglas W Hanto, Michael Curry. Patient willingness to accept liver transplantation from expanded criteria donors. *American Journal of Transplantation*. 2008;8(Suppl 2):538.
 45. K Krishnan, F Poordad, R Reddy, M Curry, OS Shaik, K Shetty, E Schiff, D Dietrich, F Regenstein, B Barin, M Peters, M Roland, P Stock, N Terrault. Safety and Efficacy of Antiviral Therapy in hepatitis C virus-human immunodeficiency virus coinfecting liver transplant recipients: preliminary HIV TR results. *American Journal of Transplantation*. 2008;8(Suppl 2):608.
 46. James R Rodrigue, Timothy Antonellis, Noelle Dimitri, Amanda Reed, Didier Mandelbrot, Martha Pavlakis, Michael Curry. Are there any benefits to being a transplant caregiver? a study of kidney and liver transplant spouses. *American Journal of Transplantation*. 2009;9(Suppl 2):619.
 47. James R Rodrigue, Timothy Antonellis, Noelle Dimitri, Amanda Reed, Didier Mandelbrot, Martha Pavlakis, Michael Curry. Psychological Impact of Transplantation on Spouse Caregivers. *American Journal of Transplantation*. 2009;9(Suppl 2):296.
 48. Martin J Dib, Peter T Kennealey, Mary Lin Farrell, Didier Mandelbrot, Michael Curry, Martin Hertl, Dicken S C Ko, Benedict Cosimi, Georgius Tsoulfas, Reza Saidi, Nahel Elias, Scott R Johnson, Douglas W Hanto, James F Markamnn, Seth J Karp. Risk factors for chronic kidney disease (CKD) after liver transplantation: Implications for performing combined liver and kidney transplantation (CLKT). *American Journal of Transplantation*. 2009;9(Suppl 2):262.
 49. Martin J Dib, Paula Ferrada, Tracy Challies, Imad Nasser, Darren D Brennan, S Nahum Goldberg, Robyn Chudzinski, Seth J Karp, Scott R Johnson, Douglas W Hanto, Michael P Curry. Tumor Burden as determined by radioloical volumetry is an accurate predictor of recurrence after liver transplantation for HCC utilizing RFA as a bridging therapy. *American Journal of Transplantation*. 2009;9(Suppl 2):445.